These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36029220)

  • 21. Invasiveness and surgical timing evaluation by clinical features of ground-glass opacity nodules in lung cancers.
    Chen PH; Chang KM; Tseng WC; Chen CH; Chao JI
    Thorac Cancer; 2019 Nov; 10(11):2133-2141. PubMed ID: 31571421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma.
    Kim HK; Choi YS; Kim J; Shim YM; Lee KS; Kim K
    J Thorac Oncol; 2010 Feb; 5(2):206-10. PubMed ID: 19901852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma.
    Xiang C; Ji C; Cai Y; Teng H; Wang Y; Zhao R; Shang Z; Guo L; Chen S; Lizaso A; Lin J; Wang H; Li B; Zhang Z; Zhao J; Wei J; Liu J; Zhu L; Fang W; Han Y
    Mod Pathol; 2022 Sep; 35(9):1181-1192. PubMed ID: 35641658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CT-guided Hookwire localization before video-assisted thoracoscopic surgery for solitary ground-glass opacity dominant pulmonary nodules: radiologic-pathologic analysis.
    Huang HZ; Wang GZ; Xu LC; Li GD; Wang Y; Wang YH; He XH; Li WT
    Oncotarget; 2017 Dec; 8(64):108118-108129. PubMed ID: 29296228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computer-Aided Nodule Assessment and Risk Yield (CANARY) may facilitate non-invasive prediction of EGFR mutation status in lung adenocarcinomas.
    Clay R; Kipp BR; Jenkins S; Karwoski RA; Maldonado F; Rajagopalan S; Voss JS; Bartholmai BJ; Aubry MC; Peikert T
    Sci Rep; 2017 Dec; 7(1):17620. PubMed ID: 29247171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cone-Beam Computed Tomography-Guided Cryobiopsy Combined with Conventional Biopsy for Ground Glass Opacity-Predominant Pulmonary Nodules.
    Huang Z; Chen J; Xie F; Liu S; Zhou Y; Shi M; Sun J
    Respiration; 2024; 103(1):32-40. PubMed ID: 38056434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules.
    Fu F; Zhang Y; Wang S; Li Y; Wang Z; Hu H; Chen H
    J Thorac Cardiovasc Surg; 2021 Aug; 162(2):451-459.e3. PubMed ID: 32711984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma.
    Miyoshi T; Aokage K; Katsumata S; Tane K; Ishii G; Tsuboi M
    Ann Thorac Surg; 2019 Jul; 108(1):249-255. PubMed ID: 30876742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers.
    Aoki T; Hanamiya M; Uramoto H; Hisaoka M; Yamashita Y; Korogi Y
    Radiology; 2012 Aug; 264(2):590-6. PubMed ID: 22653188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, pathological and radiologic features of minute pulmonary meningothelial-like nodules.
    Wen Z; Zhang Y; Fu F; Ma Z; Deng C; Ma X; Hu H; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1473-1479. PubMed ID: 34287680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
    Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
    Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor blood vessel in 3D reconstruction CT imaging as an risk indicator for growth of pulmonary nodule with ground-glass opacity.
    Xue W; Kong L; Zhang X; Xin Z; Zhao Q; He J; Wu W; Duan G
    J Cardiothorac Surg; 2023 Nov; 18(1):333. PubMed ID: 37968739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma.
    Gao RW; Berry MF; Kunder CA; Khuong AA; Wakelee H; Neal JW; Backhus LM; Shrager JB
    J Thorac Cardiovasc Surg; 2017 Dec; 154(6):2092-2099.e2. PubMed ID: 28863952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients.
    Yang W; You N; Jia M; Yeung SJ; Ou W; Yu M; Wang Y; Fu X; Zhang Z; Yang J; Lao Z; Liu Z; Zeng B; Ou Q; Wu X; Shao YW; Hong X; Wang S; Cheng C
    Lung Cancer; 2020 Aug; 146():327-334. PubMed ID: 32623075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic characterisation of pulmonary subsolid nodules: mutational landscape and radiological features.
    Li Y; Li X; Li H; Zhao Y; Liu Z; Sun K; Zhu X; Qi Q; An B; Shen D; Li R; Liu T; Mi J; Wang L; Yang F; Bai F; Wang J
    Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31699841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.